Celgene Corporation (CELG): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation ( CELG) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Celgene Corporation rose $4.66 (3.4%) to $140.65 on average volume. Throughout the day, 3,030,219 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3,010,600 shares. The stock ranged in a price between $135.81-$140.79 after having opened the day at $139.02 as compared to the previous trading day's close of $135.99. Other companies within the Drugs industry that increased today were: InterMune ( ITMN), up 15.2%, Sangamo BioSciences ( SGMO), up 11.6%, Prosensa Holding N.V ( RNA), up 9.0% and Immunomedics ( IMMU), up 7.8%.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $56.3 billion and is part of the health care sector. Shares are up 72.1% year to date as of the close of trading on Wednesday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Sequenom ( SQNM), down 29.6%, AEterna Zentaris ( AEZS), down 20.9%, OncoMed Pharmaceuticals ( OMED), down 14.2% and IntelliPharmaCeutics International ( IPCI), down 13.0% , were all laggards within the drugs industry with Alexion Pharmaceuticals ( ALXN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.